May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Serum Matrix Metalloproteinase Levels and Activities in Patients With Glaucoma
Author Affiliations & Notes
  • J. Yang
    Ophthalmology Discovery, Pharmacia Corp., St Louis, MO, United States
  • K. Zhang
    Discovery Oncology, Pharmacia Corp., St Louis, MO, United States
  • C.P. Howard
    Discovery Oncology, Pharmacia Corp., St Louis, MO, United States
  • D.L. Knoerzer
    Discovery Oncology, Pharmacia Corp., St Louis, MO, United States
  • C.F. Voliva
    Discovery Oncology, Pharmacia Corp., St Louis, MO, United States
  • D.J. Welsch
    Arthritis and Inflammation, Pharmacia Corp., St Louis, MO, United States
  • M.B. Wax
    Ophthalmology Discovery & Dept. of Ophthalmology, Pharmacia Corp.& Washington University, St Louis, MO, United States
  • Footnotes
    Commercial Relationships  J. Yang, None; K. Zhang, None; C.P. Howard, None; D.L. Knoerzer, None; C.F. Voliva, None; D.J. Welsch, None; M.B. Wax, None.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 102. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      J. Yang, K. Zhang, C.P. Howard, D.L. Knoerzer, C.F. Voliva, D.J. Welsch, M.B. Wax; Serum Matrix Metalloproteinase Levels and Activities in Patients With Glaucoma . Invest. Ophthalmol. Vis. Sci. 2003;44(13):102.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: We previously reported higher expression of matrix metalloproteinases (MMP-1, MMP-2 and MMP-3) in optic nerve heads from post-mortem glaucoma patients compared to age-matched normal controls. To further confirm the possible role of MMPs in the pathogenesis of glaucoma we assayed the levels and activities of MMPs in sera from glaucoma patients and corresponding age-matched controls. Methods: This study included 48 glaucoma patients (25 normal pressure glaucoma NPG; 23 primary open angle glaucoma POAG) and 21 age-matched controls. Selected MMPs (MMP-1, MMP-7, MMP-8, MMP-9) and TIMP-1 in the sera were assayed by ELISA. The composite MMP enzymatic activities in the sera were measured using a proprietary fluorescence peptide assay (FPA) that is efficiently cleaved by MMP-2, MMP-8, MMP-9, MMP-13 and MMP-14 but not by MMP-1, MMP-3 or MMP-7. Results: The levels of MMP-1, MMP-7, MMP-8 and TIMP-1 in the sera were similar between glaucoma patients and controls, but total MMP-9 (zymogen and active species) was decreased in the POAG group, compared with age-matched controls and the NPG group (t-test, p<0.01, and p<0.001 respectively). No difference was observed between control and POAG group. However, statistically significant increased MMP activities were observed in the NPG group by FPA assay, compared with the age-matched controls and the POAG group (t-test, p<0.01; p<0.05). There was no difference between POAG and age-matched controls (t-test, p>0.05). Conclusions: POAG patients appear to have decreased MMP-9 serum levels compared to age-matched controls, whereas increased MMP enzymatic activity was observed in the NPG patients. These results suggest that MMPs may have a role in the initiation and/or sustainment of glaucomatous optic neuropathy in some patients.

Keywords: enzymes/enzyme inhibitors • clinical research methodology 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×